Related Experiment Video
Updated: Aug 9, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Development and Characterization of a Patient-Derived KIF5B-RET Fusion Lung Adenocarcinoma Cell Line for Subcutaneous
Akihiro Nishiyama1, Shigeki Sato1, Hiroyuki Sakaguchi1
1Department of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan.
Introduction:
This study presents the development and characterization of a novel lung adenocarcinoma cell line with kinesin family member 5B rearranged during transfection (KIF5B-RET) fusion, derived from a single patient's pleural effusion.
Methods:
A pleural effusion sample was collected from a patient with RET fusion-positive NSCLC. The cell line was developed from the pleural effusion, and its characteristics were investigated in vitro and in vivo. Information on lung cancer cell lines with RET fusions was collected through a literature review. The characteristics of the RET fusion-positive cell line developed were then compared with information on RET fusion-positive cell lines identified in the literature.
Results:
The newly established PB302 cell line has the following three key characteristics: high sensitivity to selective RET inhibitors, the ability to grow in the central nervous system, and the ability to grow subcutaneously in immunodeficient mice. These features enabled the development of central nervous system disease and subcutaneous tumor models. A comparative analysis revealed that PB302 uniquely possesses these characteristics among RET-positive lung adenocarcinoma cell lines.
Conclusions:
This cell line highlights several potentials as a tool for preclinical research and drug development.
Insights
A new lung adenocarcinoma cell line, PB302, with a KIF5B-RET fusion was developed. This novel cell line shows sensitivity to RET inhibitors and can model central nervous system and subcutaneous tumors for research.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) with RET fusions represents a targetable subset.
- Development of relevant preclinical models is crucial for advancing therapeutic strategies.
Purpose of the Study:
- To develop and characterize a novel cell line from a RET fusion-positive NSCLC patient.
- To establish a preclinical model for studying KIF5B-RET fusions and evaluating targeted therapies.
Main Methods:
- A patient-derived cell line (PB302) was established from pleural effusion of a RET fusion-positive NSCLC patient.
- In vitro and in vivo characterization of the PB302 cell line was performed.
- Comparative analysis with existing RET-fusion positive lung adenocarcinoma cell lines was conducted.
Main Results:
- The PB302 cell line exhibits high sensitivity to selective RET inhibitors.
- PB302 demonstrates the ability to grow in the central nervous system and subcutaneously in immunodeficient mice.
- These characteristics enable the development of CNS disease and subcutaneous tumor models, unique among RET-positive cell lines.
Conclusions:
- The novel PB302 cell line serves as a valuable tool for preclinical research in RET fusion-positive lung adenocarcinoma.
- This model holds significant potential for drug development and evaluating novel therapeutic interventions.
